<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate factors involved in global forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion, the effects of the systemically administered NOS inhibitor, N(G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>), on changes in extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and cerebral blood flow (CBF) were studied during the early period of global forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion, simultaneously measuring the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> released in the rat forebrain cortex and cortical CBF </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: After injection of saline or L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion was performed by bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> with controlled hemorrhagic <z:hpo ids='HP_0002615'>hypotension</z:hpo> (30 mmHg) for 10 min and reperfusion for 60 min </plain></SENT>
<SENT sid="2" pm="."><plain>The microdialysis electrode and laser Doppler flowmetry were used for real-time monitoring of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and CBF, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: During <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> increased linearly to over 100 muM and remained elevated 30 min after reperfusion in L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>-treated rats </plain></SENT>
<SENT sid="4" pm="."><plain>In L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>-treated rats, CBF also remained significantly lower than baseline for 30-60 min after reperfusion, and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> was higher than in saline-treated rats throughout the experiment </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: A remarkable linear increase in <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release was observed during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> did not prevent this dramatic <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> accumulation, and moreover, its level increased during reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>The decrease in CBF response after reperfusion might be a factor of the elevated <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> after reperfusion due to a decrease in reuptake of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> </plain></SENT>
</text></document>